Latest News
RHI set to Present groundbreaking POC data at the Annual MidWindter Meeting (2/24) for the Association for Research in Otolaryngology(ARO)
Gene Therapy to Treat Mouse Model of Human Recessive Deafness Caused by a TMPRSS3 Mutation (ABSRTRACT) Annual MidWinter Meeting Background: Expected to afflict every one
Dr. Holt wins the 2021 ARO Virtual MidWinter Meeting Pioneer Award in Basic Science
We want to congratulate our very own Dr. Jeff Holt for winning the 2021 ARO Virtual MidWinter Meeting Pioneer Award in Basic Science. This is
Interview with Dr. Jeff Holt
We sat down with Dr. Jeff Holt and asked him about why he joined the RHI team, what he’s currently working on, how COVID-19 has
RESCUE HEARING INC. ANNOUNCES ADDITION OF BUSINESS ADVISOR ANDREW KOOPMAN
Andrew Koopman joins RHI with more than 30 years in the Biotechnology and Biomedical industries. He is currently, a business development consultant and strategic advisor, working with universities, investors, biotechnology/biomedical startups, and incubators.
Rescue Hearing Inc. Announces Addition of Drug Development Advisor Dr. Lee Golden
GAINESVILLE- September 24, 2020- Rescue Hearing Inc (RHI), a team of visionary, internationally recognized physicians, scientists, and bioengineers focused on developing new gene therapies to
Rescue Hearing Inc. Announces Addition of Drug Manufacturing and CMC Advisor Mike Zdanowski
GAINESVILLE- September 1, 2020- Rescue Hearing Inc., a team of visionary, internationally recognized physicians, scientists, and bioengineers focused on developing new gene therapies to eliminate
RHI CEO Explains Natural History
Our CEO Jim Ayala explains what “Natural History” is and why it’s so important to gene therapy progress. Keeping watching to hear how RHI
RHI CEO Gives an Update on Progress
Our CEO Jim Ayala recently gave an update on RHI’s progress. Watch to hear what our team has accomplished and what the next steps
The Next Logical Step: Rescue Hearing Inc.
THE NEXT LOGICAL STEP In January 2015, I read a New York Times article by Andrew Pollack entitled “Ear Ailments are New Focus for Drugs
“Build-to-Buy”: A Novel Funding Mechanism to Advance Hearing Loss Science and Commercialization
The “Build-to-Buy”Framework Three parties are used: (a) a science company with a novel technology, (b) a venture capital firm and (c) a big pharma company.
Genvec: A Cutting Edge Company
First-in-man Somebody’s got to be the first, the pioneer, the risk taker. Two publicly traded companies, Genvec (NASDAQ:GNVC) and its big pharma partner, Novartis (NYSE:NVS)
Rescue Hearing Inc signs Sponsored Research Agreement with University of Kansas Medical Center Research Institute
AUGUST 2018: Rescue Hearing Inc (RHI) has signed a Sponsored Research Agreement with the University of Kansas Medical Center Research Institute. RHI will be conducting
